[go: up one dir, main page]

WO1996018410A1 - Agent de traitement du cancer primitif du foie et procede de traitement du cancer primitif du foie - Google Patents

Agent de traitement du cancer primitif du foie et procede de traitement du cancer primitif du foie Download PDF

Info

Publication number
WO1996018410A1
WO1996018410A1 PCT/RU1995/000030 RU9500030W WO9618410A1 WO 1996018410 A1 WO1996018410 A1 WO 1996018410A1 RU 9500030 W RU9500030 W RU 9500030W WO 9618410 A1 WO9618410 A1 WO 9618410A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
ρaκa
dοκsορubitsin
πecheni
πeρvichnοgο
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU1995/000030
Other languages
English (en)
Russian (ru)
Inventor
Alexandr Vasilievich Tikhonov
Vladimir Mikhailovich Scherbakov
Valery Igorevich Volodarsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU19641/95A priority Critical patent/AU1964195A/en
Publication of WO1996018410A1 publication Critical patent/WO1996018410A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the primary equipment of the liver is one of the most malignant human subjects.
  • the treatment of painful diseases is a difficult task.
  • a chance for a cure is given by an operation performed at an earlier stage of illness, but more often in the tumor process, they are involved in the treatment of the liver. Otherwise, there is a cirrhosis, massive thrombosis and infiltration of the direct vein is treated as an indication of the operation; Potentially cost-effective can be considered up to 30% of patients.
  • the resulting complications are severe, and the recurrence of the disease is faster than the exception. Therefore, the overwhelmingly large number of patients with primary liver disease are not recommended for treatment.
  • the primary liver treatment is related to the number of malignant forms of malignant drugs.
  • this compound was synthesized as a commercially available material for X-ray examinations (Ka ⁇ a ⁇ .et.a.
  • the ultrafluid liqueur is a specialty seed oil that has been replaced with ethyl ether for glycerin ether.
  • the viscosity of compounds at 15 ° C is 70 ss, and the density is at 15 ° C -1.28. 1g
  • the ultrafluid liquor contains 0.38 g of iodine. With the internal introduction of the lipid, the ultrafluid is dispersed into small fatty droplets.
  • the liver of a liver can be stored for up to 3 months, but it is slightly mild. From normal tkane lipidul ultrafluid output in the average in 24 hours. This property was used for direct delivery of medical supplies in the liver of the liver of the liver. The patient received a direct treatment of the patient and the patient was introduced into the patient ultrapluid.
  • the user of the ultrafluid serves as a convenient way of doing business, so that you can ⁇ a ⁇ ⁇ azali further issled ⁇ vaniya me ⁇ d ⁇ n ⁇ ⁇ zv ⁇ lyae ⁇ uvelichiva ⁇ e ⁇ e ⁇ ivn ⁇ s ⁇ ⁇ imi ⁇ e ⁇ a ⁇ ev ⁇ iches ⁇ g ⁇ v ⁇ zdeys ⁇ viya ⁇ i ⁇ e ⁇ a ⁇ ii ⁇ e ⁇ vichn ⁇ g ⁇ ⁇ a ⁇ a ⁇ echeni 2.5-3 ⁇ aza ⁇ s ⁇ avneniyu with ⁇ ezul ⁇ a ⁇ ami observed ⁇ i ⁇ imenenii ⁇ iv ⁇ u ⁇ lev ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a in sv ⁇ b ⁇ dn ⁇ m form.
  • D ⁇ m Deich v ⁇ e ⁇ vye was s ⁇ muli ⁇ vana and za ⁇ em e ⁇ s ⁇ e ⁇ imen ⁇ aln ⁇ ⁇ d ⁇ ve ⁇ zhdena gi ⁇ eza ⁇ v ⁇ zm ⁇ zhn ⁇ s ⁇ i na ⁇ avlenn ⁇ g ⁇ ⁇ ans ⁇ a ⁇ iv ⁇ u ⁇ levy ⁇ ⁇ e ⁇ a ⁇ a ⁇ v in ne ⁇ ye kinds ⁇ u ⁇ levy ⁇ ⁇ le ⁇ with is ⁇ lz ⁇ vaniem in ⁇ aches ⁇ ve ⁇ ans ⁇ n ⁇ g ⁇ bel ⁇ a al ⁇ a- ⁇ e ⁇ ein ( ⁇ ei ⁇ ⁇ .G., ⁇ .Sa ⁇ seg ⁇ ez., 1991, 56, 253-312 )
  • the essence of the recently proposed method is as follows.
  • P ⁇ s ⁇ avlennaya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in s ⁇ eds ⁇ ve for ⁇ davleniya ⁇ s ⁇ a ⁇ u ⁇ levy ⁇ ⁇ le ⁇ ⁇ e ⁇ vichn ⁇ g ⁇ ⁇ a ⁇ a ⁇ echeni, s ⁇ de ⁇ zhaschem deys ⁇ vuyuschee vesches ⁇ v ⁇ and n ⁇ si ⁇ el in ⁇ aches ⁇ ve ⁇ g ⁇ is ⁇ lz ⁇ van li ⁇ i ⁇ d ⁇ l ul ⁇ a ⁇ luid, s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu in ⁇ aches ⁇ ve deys ⁇ vuyuscheg ⁇ vesches ⁇ va is ⁇ lz ⁇ van d ⁇ s ⁇ ubitsin-es ⁇ n and n ⁇ si ⁇ el d ⁇ lni ⁇ eln ⁇ s ⁇ de ⁇ zhi ⁇ li ⁇ ilizi ⁇ vanny ⁇
  • ⁇ ya is ⁇ lz ⁇ vaniya li ⁇ i ⁇ d ⁇ l ul ⁇ a ⁇ luida izves ⁇ n ⁇ for d ⁇ s ⁇ av ⁇ i in ⁇ u ⁇ levye ⁇ ani deys ⁇ vuyuscheg ⁇ vesches ⁇ va, ⁇ edlagaem ⁇ e s ⁇ che ⁇ anie de ⁇ s ⁇ ubitsin-es ⁇ na and li ⁇ i ⁇ d ⁇ l ul ⁇ a ⁇ luida with d ⁇ bav ⁇ y li ⁇ ilizi ⁇ vann ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a al ⁇ a- ⁇ e ⁇ eina chel ⁇ ve ⁇ a ⁇ bes ⁇ echivae ⁇ not ⁇ l ⁇ na ⁇ avlennuyu d ⁇ s ⁇ av ⁇ u d ⁇ s ⁇ ubitsin-es ⁇ na in ⁇ u ⁇ levye, n ⁇ not n ⁇ malnye ⁇ le ⁇ i, n ⁇ and ⁇ bes
  • Dosububicin-estrogen may be obtained as described in ⁇ , ⁇ , ⁇ 2026687.
  • dubrucin-estrogen is a very dark-colored, small-sized industrial unit with 49 ⁇ 47 ° 15 ⁇ molar mass of 895.96 and more
  • ' ⁇ aib ⁇ lee tseles ⁇ b ⁇ azn ⁇ is ⁇ lz ⁇ va ⁇ following s ⁇ n ⁇ sheniya deys ⁇ vuyuscheg ⁇ vesches ⁇ va and n ⁇ si ⁇ elya with d ⁇ bav ⁇ y: ⁇ as ⁇ v ⁇ d ⁇ s ⁇ ubitsin-es ⁇ n 96% e ⁇ il ⁇ v ⁇ m s ⁇ i ⁇ e in ⁇ liches ⁇ ve 20-60 mg 10-15 ml li ⁇ i ⁇ d ⁇ l ul ⁇ a ⁇ luida and 2-10 mg al ⁇ a- ⁇ eina chel ⁇ ve ⁇ a 12-15 ml ⁇ iz ⁇ as ⁇ v ⁇ a , and it is advisable to use the product of a good rubicin extract in heat up to 70-76 ° C with ethyl alcohol.
  • the lyophilized, sterile product of the alpha-fetal solution is administered internally in the amount of 2-10 mg in 12-15 ml of the physiological solution.
  • the resulting product is converted to 10-15 ml of a pre-treated ultrafluidide.
  • the resulting suspension is cooled to 32-37 ° C and put in front of the X-ray television control in liver therapy. After 3-4 weeks, administer the direct injections of the alpha-fetothepatein and the compound-estericidal compound described above.
  • ENG clinical analyzes of blood and urine, laparoscopy, distinction in blood of alpha-fetus, angiography, cardiac arrest, ulceration.
  • the method is used as described above, that is, there is a preliminary process for the transmission of liver arteries.
  • Lyserized sterile alpha is administered internally in the amount of 2-10 mg in 12 ml of physiological solution.
  • sterile substances in the range of 20-60 mg of a solution of 0.5-1.5% of solution are obtained.
  • the resulting product is converted to 10-15 ml of a pre-heated ultrafluid.
  • the resulting slurry is cooled to 37 ° C and put the X-ray television control in the liver therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un agent destiné à supprimer la croissance de cellules tumorales dans le cancer primitif du foie. Il contient de la doxorubicine-estrone en tant que substance active et du lipiodol ultrafluide en tant qu'excipient, ce dernier contenant une préparation lyophilisée de f÷toprotéine alpha humaine. Le procédé proposé de traitement du cancer primitif du foie consiste en la préparation d'une solution de la substance active dans du lipiodol ultrafluide avec addition de f÷toprotéine alpha.
PCT/RU1995/000030 1994-12-13 1995-02-22 Agent de traitement du cancer primitif du foie et procede de traitement du cancer primitif du foie Ceased WO1996018410A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19641/95A AU1964195A (en) 1994-12-13 1995-02-22 Agent for treating primary liver cancer and a method of treating primary liver cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU94042656 1994-12-13
RU9494042656A RU2065307C1 (ru) 1994-12-13 1994-12-13 Способ лечения первичного рака печени и набор для лечения первичного рака печени

Publications (1)

Publication Number Publication Date
WO1996018410A1 true WO1996018410A1 (fr) 1996-06-20

Family

ID=20162826

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1995/000030 Ceased WO1996018410A1 (fr) 1994-12-13 1995-02-22 Agent de traitement du cancer primitif du foie et procede de traitement du cancer primitif du foie

Country Status (3)

Country Link
AU (1) AU1964195A (fr)
RU (1) RU2065307C1 (fr)
WO (1) WO1996018410A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2134589C1 (ru) * 1998-12-22 1999-08-20 Зубов Дмитрий Львович Способ лечения первичного рака печени и набор для лечения первичного рака печени
RU2165775C1 (ru) * 2000-06-21 2001-04-27 Центральный научно-исследовательский рентгено-радиологический институт Способ лечения цирроза печени
RU2179452C1 (ru) * 2000-06-22 2002-02-20 Пак Владимир Николаевич Способ лечения злокачественных новообразований и комплексный препарат, обладающий противоопухолевым действием, для осуществления способа
RU2244551C2 (ru) * 2002-10-09 2005-01-20 Плеханов Леонид Александрович Способ лечения моторно-вегетативных нарушений у детей
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
CN101137386A (zh) * 2005-03-08 2008-03-05 大鹏药品工业株式会社 肝癌的治疗方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200090A2 (fr) * 1985-04-19 1986-11-05 Oncogene Science, Inc. Inhibiteurs tissulaires de croissance de tumeur, méthodes de préparation et utilisations
EP0299528A1 (fr) * 1987-07-16 1989-01-18 Bristol-Myers Squibb Company Solution non-aqueuse de chlorhydrate de doxorubicine
WO1989008662A1 (fr) * 1988-03-11 1989-09-21 Boris Cercek Facteur general de detection de scm lie au cancer; preparation et procede d'utilisation
WO1989009610A1 (fr) * 1988-04-13 1989-10-19 Cetus Corporation Formulations de facteur de necrose tumorale
US4888172A (en) * 1982-09-23 1989-12-19 Alfaceu Corporation Pharmaceutical for treating tumors and methods for making it
WO1992009294A1 (fr) * 1990-11-28 1992-06-11 Barnea Eytan R Proteines purifiees tirees de tissu gestationnel mammifere regulant la proliferation cellulaire
EP0608108A1 (fr) * 1993-01-19 1994-07-27 Arizona Board Of Regents Extraction et structure de halistatin 1, et leur utilisation comme agent antitumorale

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888172A (en) * 1982-09-23 1989-12-19 Alfaceu Corporation Pharmaceutical for treating tumors and methods for making it
EP0200090A2 (fr) * 1985-04-19 1986-11-05 Oncogene Science, Inc. Inhibiteurs tissulaires de croissance de tumeur, méthodes de préparation et utilisations
EP0299528A1 (fr) * 1987-07-16 1989-01-18 Bristol-Myers Squibb Company Solution non-aqueuse de chlorhydrate de doxorubicine
WO1989008662A1 (fr) * 1988-03-11 1989-09-21 Boris Cercek Facteur general de detection de scm lie au cancer; preparation et procede d'utilisation
WO1989009610A1 (fr) * 1988-04-13 1989-10-19 Cetus Corporation Formulations de facteur de necrose tumorale
WO1992009294A1 (fr) * 1990-11-28 1992-06-11 Barnea Eytan R Proteines purifiees tirees de tissu gestationnel mammifere regulant la proliferation cellulaire
EP0608108A1 (fr) * 1993-01-19 1994-07-27 Arizona Board Of Regents Extraction et structure de halistatin 1, et leur utilisation comme agent antitumorale

Also Published As

Publication number Publication date
RU2065307C1 (ru) 1996-08-20
AU1964195A (en) 1996-07-03
RU94042656A (ru) 1997-06-10

Similar Documents

Publication Publication Date Title
Greenberg et al. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system
Blumberg et al. Clinical trials of WR-2721 with radiation therapy
US4481195A (en) Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals
WO1994001099A1 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectrice et anti-cholera
AU723812B2 (en) Medicinal preparation and a method of medicinal action on human organism
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d'ulceres peptiques
US6720011B1 (en) Injectable composition for cancer treatment
WO2005039636A1 (fr) Produit pour potentialiser les effets curatifs et intensifier l'action d'un medicament
WO1996018410A1 (fr) Agent de traitement du cancer primitif du foie et procede de traitement du cancer primitif du foie
RU2123827C1 (ru) Способ лечения злокачественных опухолей
JP2013060447A (ja) ボーラスまたは間欠的な静脈内注入による、抗内毒素薬の投与
Blumberg et al. Successful treatment of ischaemic ulceration of the skin in azotaemic hyperparathyroidism with parathyroidectomy
RU2252778C1 (ru) Применение трипептида pro-gly-pro в качестве средства профилактики и лечения диабета, способ профилактики и лечения диабета и фармацевтическая композиция для профилактики и лечения диабета
RU2084217C1 (ru) Лекарственное средство
Godlowski Stimulation of the Suprarenal Glands in the Treatment of Rheumatoid Arthritis: Preliminary Report
US20030077257A1 (en) Method for preventing and curing diseases of an immune system and a remedy for carrying out said method
RU2134589C1 (ru) Способ лечения первичного рака печени и набор для лечения первичного рака печени
RU2137477C1 (ru) Способ лечения заболеваний, характеризующихся аутоиммунной агрессией
RU2078571C1 (ru) Способ лечения хронических гепатитов
RU2157218C2 (ru) Способ иммунотерапии хронических воспалительных заболеваний
RU2185843C2 (ru) Способ лечения заболеваний печени и желчевыводящих путей
RU2164416C2 (ru) Способ лечения ревматоидного артрита
RU2129435C1 (ru) Антидиабетогенное средство
RU2321395C1 (ru) Способ лечения больных акантолитической пузырчаткой
SU1009468A1 (ru) Способ лечени идиопатического дерматомиозита

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA